Stockreport

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics, Inc.  (CATX) 
PDF Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melano [Read more]